Literature DB >> 18029234

Diagnostic multiplex PCR assay for the identification of the Liverpool, Midlands 1 and Manchester CF epidemic strains of Pseudomonas aeruginosa.

Joanne L Fothergill1, Anna L Upton, Tyrone L Pitt, C Anthony Hart, Craig Winstanley.   

Abstract

Individual PCR amplification tests have been developed for three UK CF epidemic strains, the Liverpool epidemic strain (LES), Midlands 1 and the Manchester epidemic strain (MES). We report a simple diagnostic multiplex PCR test that can be used to screen for all three of these strains. To evaluate the test, we screened collections of LES, MES and Midlands 1 isolates, along with various CF and non-CF non-epidemic Pseudomonas aeruginosa strains. The test was 100% sensitive and 100% specific in the identification of these UK CF epidemic strains.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 18029234     DOI： 10.1016/j.jcf.2007.09.002

Source DB:  PubMed          Journal:  J Cyst Fibros        ISSN： 1569-1993            Impact factor:   5.482


  9 in total

Review 1.  Epidemiology, Biology, and Impact of Clonal Pseudomonas aeruginosa Infections in Cystic Fibrosis.

Authors:  Michael D Parkins; Ranjani Somayaji; Valerie J Waters
Journal:  Clin Microbiol Rev       Date:  2018-08-29       Impact factor: 26.132

2.  Impact of Pseudomonas aeruginosa genomic instability on the application of typing methods for chronic cystic fibrosis infections.

Authors:  Joanne L Fothergill; Judith White; Juliet E Foweraker; Martin J Walshaw; Martin J Ledson; Eshwar Mahenthiralingam; Craig Winstanley
Journal:  J Clin Microbiol       Date:  2010-04-21       Impact factor: 5.948

3.  Comparison of three typing methods for Pseudomonas aeruginosa isolates from patients with cystic fibrosis.

Authors:  V Waters; J E A Zlosnik; Y C W Yau; D P Speert; S D Aaron; D S Guttman
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2012-07-29       Impact factor: 3.267

4.  Development and Validation of a PCR Assay To Detect the Prairie Epidemic Strain of Pseudomonas aeruginosa from Patients with Cystic Fibrosis.

Authors:  M Workentine; A Poonja; B Waddell; J Duong; D G Storey; D Gregson; R Somayaji; H R Rabin; M G Surette; M D Parkins
Journal:  J Clin Microbiol       Date:  2015-12-09       Impact factor: 5.948

5.  A diagnostic PCR assay for the detection of an Australian epidemic strain of Pseudomonas aeruginosa.

Authors:  Heidi L Williams; Lynne Turnbull; Susan J Thomas; Anna Murphy; Tim Stinear; David S Armstrong; Cynthia B Whitchurch
Journal:  Ann Clin Microbiol Antimicrob       Date:  2010-07-16       Impact factor: 3.944

6.  Newly introduced genomic prophage islands are critical determinants of in vivo competitiveness in the Liverpool Epidemic Strain of Pseudomonas aeruginosa.

Authors:  Craig Winstanley; Morgan G I Langille; Joanne L Fothergill; Irena Kukavica-Ibrulj; Catherine Paradis-Bleau; François Sanschagrin; Nicholas R Thomson; Geoff L Winsor; Michael A Quail; Nicola Lennard; Alexandra Bignell; Louise Clarke; Kathy Seeger; David Saunders; David Harris; Julian Parkhill; Robert E W Hancock; Fiona S L Brinkman; Roger C Levesque
Journal:  Genome Res       Date:  2008-12-01       Impact factor: 9.043

7.  Halting the spread of epidemic pseudomonas aeruginosa in an adult cystic fibrosis centre: a prospective cohort study.

Authors:  Abdul Ashish; Matthew Shaw; Craig Winstanley; Linda Humphreys; Martin J Walshaw
Journal:  JRSM Short Rep       Date:  2013-01-14

8.  Health-related quality of life in Cystic Fibrosis patients infected with transmissible Pseudomonas aeruginosa strains: cohort study.

Authors:  Abdul Ashish; Matthew Shaw; James McShane; Martin J Ledson; Martin J Walshaw
Journal:  JRSM Short Rep       Date:  2012-02-27

9.  Extensive diversification is a common feature of Pseudomonas aeruginosa populations during respiratory infections in cystic fibrosis.

Authors:  Abdul Ashish; Steve Paterson; Eilidh Mowat; Joanne L Fothergill; Martin J Walshaw; Craig Winstanley
Journal:  J Cyst Fibros       Date:  2013-05-01       Impact factor: 5.482
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.